Aptiom
Named-patient access overview. Aptiom is coordinated by Reserve Meds for international patients via physician-led cross-border sourcing.
Quick orientation
Aptiom (eslicarbazepine acetate) is an oral, once-daily antiseizure medication developed approximately by Sumitomo Pharma America (formerly Sunovion), with US FDA approval in 2013 for partial-onset (focal-onset) seizures as monotherapy or adjunctive therapy in patients 4 years and older. It is a third-generation member of the carbamazepine and oxcarbazepine voltage-gated sodium channel modulator family, with a once-daily dosing profile that contrasts with the twice-daily dosing of oxcarbazepine and the multi-times-daily dosing of immediate-release carbamazepine.
Case active and ready to skip the regulatory walkthrough? Start your case or WhatsApp us.
How Reserve Meds coordinates Aptiom
- Patient or treating physician submits an intake at the patient portal.
- Reserve Meds clinical team verifies appropriateness for the patient and destination country.
- Treating physician issues prescription and clinical justification.
- Country-specific named-patient documentation is prepared.
- Aptiom is sourced from a DSCSA-compliant US specialty wholesaler with full serial traceability.
- Shipment is coordinated to the patient's physician or hospital pharmacy with appropriate handling.
Access by country
Reserve Meds publishes a detailed country deep-dive for Aptiom in every market we coordinate. Each page below covers the destination-country regulatory pathway, real costs, indicative timelines, physician-credential requirements, and handling notes. Tap any country to read the full deep-dive.
Start a request for Aptiom
Submit a 60-second intake. The clinical team will follow up within 24 hours with case-specific feasibility, timeline, and a formal quote.